CASE REPORT article
Front. Oncol.
Sec. Skin Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1530871
Primary Mucinous Carcinoma of the Skin with Co-expression of TRPS1 and GATA3: A Case Report
Provisionally accepted
- 1the Second School of Clinical Medicine of Binzhou Medical University, Yantai, China
- 2Department of Pathology, Yantai Yuhuangding Hospital, Yantai, Shandong Province, China
- 3Department of Dermatology, Laishan Branch of Yantai Yuhuangding Hospital, Yantai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Primary cutaneous mucinous carcinoma (PCMC) is a rare malignant neoplasm, with approximately 450 cases reported worldwide to date. Its histological features closely resemble those of mucinous carcinoma of the breast, posing significant diagnostic challenges. We report a case of PCMC occurring at the upper margin of the eyelid in a 65-year-old male who presented with a painless, progressively enlarging mass over a four-year period. Histopathological examination following surgical excision confirmed the diagnosis of PCMC, with immunohistochemical staining demonstrating co-expression of TRPS1 and GATA3. This case highlights several key clinical and pathological characteristics of PCMC. The tumor typically affects middle-aged to elderly males and demonstrates low metastatic potential but a high rate of local recurrence. Histologically, it is difficult to distinguish from cutaneous metastatic mucinous carcinoma (MMC), particularly of breast origin. In this context, the co-expression of TRPS1 and GATA3 necessitates careful interpretation, as these markers are not exclusive to PCMC. The diagnostic utility of TRPS1 lies not in its individual specificity, but rather in its combined use with other markers such as GATA3. Radical surgical excision remains the mainstay of treatment, with adjuvant endocrine therapy considered in ER/PR-positive cases. Compared to cutaneous MMC, PCMC generally carries a more favorable prognosis, reinforcing the importance of early and accurate diagnosis. Ultimately, the diagnosis of PCMC relies on a comprehensive evaluation that integrates clinical presentation, imaging findings, histological architecture, and immunohistochemical profiles.PCMC is a rare malignant adnexal neoplasm that originates from eccrine or, more likely, apocrine glands (1, 2). It most frequently arises in apocrine-rich regions, particularly the head and neck area, and exhibits indolent behavior characterized by low metastatic potential but a high rate of local recurrence (3-7). Despite its slow growth, PCMC poses significant diagnostic challenges due to its histological resemblance to metastatic mucinous carcinoma (MMC), especially breast-derived variants (8-10).
Keywords: PCMC, TRPS1, GATA3, co-expression, differential diagnosis
Received: 19 Nov 2024; Accepted: 13 Aug 2025.
Copyright: © 2025 Song, Jiang, Gao and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guohua Yu, Department of Pathology, Yantai Yuhuangding Hospital, Yantai, Shandong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.